A patient with HIV develops tuberculosis. When should ART be initiated?

Explanation

## Correct Answer: C. Start ATT, then ART after 2 weeks The timing of ART initiation in TB-HIV coinfection is critical to prevent immune reconstitution inflammatory syndrome (IRIS) and treatment failure. According to WHO guidelines and Indian NTEP (National TB Elimination Programme) recommendations, **ATT should be started first, followed by ART after 2 weeks**. This staggered approach allows the patient to tolerate ATT, establish drug levels, and reduce the risk of TB-IRIS—a paradoxical worsening of TB symptoms when CD4+ count rapidly recovers after ART initiation. The 2-week window is the evidence-based interval that balances early immune reconstitution with safety. In resource-limited settings like India, this sequential approach also allows monitoring for ATT-related hepatotoxicity and drug interactions before adding ART. For patients with CD4 <50 cells/μL, ART may be started within 2 weeks of ATT initiation, but the principle remains: ATT first, then ART. This approach is endorsed by the Indian Academy of Pediatrics (IAP) and RNTCP guidelines for both adult and pediatric populations. ## Why the other options are wrong **A. Start ART followed by ATT** — This is wrong because starting ART before ATT risks rapid CD4 recovery triggering severe TB-IRIS, with paradoxical worsening of TB symptoms, fever, and lymphadenitis. Additionally, ART initiation without active TB treatment allows uncontrolled TB replication, leading to treatment failure and drug resistance. Indian NTEP guidelines explicitly contraindicate this sequence. **B. ART alone** — This is wrong because TB requires specific anti-tuberculous therapy (ATT) to achieve microbiological cure and prevent dissemination. ART alone cannot treat active TB; it only provides immune reconstitution. This approach violates RNTCP standards and would result in TB progression, drug-resistant TB, and death. It is never indicated in TB-HIV coinfection. **D. Start ART and ATT simultaneously** — This is wrong because simultaneous initiation increases the risk of TB-IRIS, hepatotoxicity from overlapping drug toxicity, and poor adherence due to high pill burden. The 2-week staggered approach allows tolerance assessment and reduces immune reconstitution complications. Simultaneous initiation is only considered in advanced immunosuppression (CD4 <50) with specific clinical judgment, not as routine practice per Indian guidelines. ## High-Yield Facts - **TB-IRIS** occurs when CD4 recovery after ART causes paradoxical worsening of TB symptoms; prevented by starting ATT first and delaying ART by 2 weeks. - **NTEP-ART guideline**: Start ATT immediately, initiate ART after 2 weeks in most TB-HIV patients; earlier ART (within 2 weeks) only for CD4 <50 cells/μL. - **Drug interactions**: Rifampicin induces CYP3A4, reducing protease inhibitor and NNRTI levels; sequential initiation allows dose adjustment of ART. - **Hepatotoxicity risk**: Both ATT (INH, RIF, PZA) and some ART drugs (NVP, PI) are hepatotoxic; staggered start allows monitoring of liver function. - **Immune reconstitution timing**: CD4 recovery typically begins 2–4 weeks after ART; the 2-week ATT lead-in reduces TB antigen load before immune surge. ## Mnemonics **ATT First, ART Later (2 weeks)** **A**TT **F**irst = **A**void **F**IRIS. Start TB drugs immediately, then add ART after 2 weeks. Prevents immune reconstitution inflammatory syndrome and allows ATT tolerance. **IRIS Prevention: Sequential > Simultaneous** **S**equential (ATT → ART after 2 weeks) reduces **IRIS** risk. **S**imultaneous increases pill burden, hepatotoxicity, and immune paradox. Use in India per NTEP guidelines. ## NBE Trap NBE may lure students with the intuition that "earlier ART = better immune recovery," causing them to choose simultaneous initiation (option D) or ART-first (option A). The trap is ignoring the **temporal biology of IRIS**—CD4 recovery must be gradual and TB antigen load must be reduced first, or immune reconstitution becomes inflammatory rather than protective. ## Clinical Pearl In Indian TB clinics, a patient with TB-HIV presenting with CD4 200 cells/μL should start ATT immediately (RIPE regimen per RNTCP) and return for ART initiation 2 weeks later. If CD4 <50, ART may start within 2 weeks, but ATT always comes first. This sequence has reduced TB-IRIS mortality in Indian cohorts and is the standard of care across NTEP centers. _Reference: RNTCP Guidelines on TB-HIV Management (India); WHO Consolidated Guidelines on TB-HIV (2019); Harrison's Principles of Internal Medicine, Ch. 197 (Tuberculosis); KD Tripathi Pharmacology, Ch. 51 (Antiretrovirals)_